Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Identifieur interne : 002013 ( Main/Exploration ); précédent : 002012; suivant : 002014Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Auteurs : Steven E. Nissen [États-Unis] ; Erik Stroes [Pays-Bas] ; Ricardo E. Dent-Acosta [États-Unis] ; Robert S. Rosenson [États-Unis] ; Sam J. Lehman [Australie] ; Naveed Sattar [Royaume-Uni] ; David Preiss [Royaume-Uni] ; Eric Bruckert [France] ; Richard Ceška [République tchèque] ; Norman Lepor [États-Unis] ; Christie M. Ballantyne [États-Unis] ; Ioanna Gouni-Berthold [Allemagne] ; Mary Elliott [États-Unis] ; Danielle M. Brennan [États-Unis] ; Scott M. Wasserman [États-Unis] ; Ransi Somaratne [États-Unis] ; Rob Scott [États-Unis] ; Evan A. Stein [États-Unis]Source :
- JAMA [ 1538-3598 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticholestérolémiants (effets indésirables), Anticholestérolémiants (usage thérapeutique), Anticorps monoclonaux (effets indésirables), Anticorps monoclonaux (usage thérapeutique), Atorvastatine de calcium (effets indésirables), Cholestérol LDL (sang), Creatine kinase (sang), Facteurs temps, Femelle, Humains, Hypercholestérolémie (sang), Hypercholestérolémie (traitement médicamenteux), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (effets indésirables), Maladies musculaires (), Maladies musculaires (sang), Marqueurs biologiques (sang), Myalgie (), Myalgie (sang), Myosite (), Myosite (sang), Mâle, Méthode en double aveugle, Rhabdomyolyse (), Rhabdomyolyse (sang), Études croisées, Ézétimibe (effets indésirables), Ézétimibe (usage thérapeutique).
- MESH :
- effets indésirables : Anticholestérolémiants, Anticorps monoclonaux, Atorvastatine de calcium, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Ézétimibe.
- sang : Cholestérol LDL, Creatine kinase, Hypercholestérolémie, Maladies musculaires, Marqueurs biologiques, Myalgie, Myosite, Rhabdomyolyse.
- traitement médicamenteux : Hypercholestérolémie.
- usage thérapeutique : Anticholestérolémiants, Anticorps monoclonaux, Ézétimibe.
- Adulte, Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Maladies musculaires, Myalgie, Myosite, Mâle, Méthode en double aveugle, Rhabdomyolyse, Études croisées.
English descriptors
- KwdEn :
- Adult, Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal (therapeutic use), Anticholesteremic Agents (adverse effects), Anticholesteremic Agents (therapeutic use), Atorvastatin Calcium (adverse effects), Biomarkers (blood), Cholesterol, LDL (blood), Creatine Kinase (blood), Cross-Over Studies, Double-Blind Method, Ezetimibe (adverse effects), Ezetimibe (therapeutic use), Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects), Hypercholesterolemia (blood), Hypercholesterolemia (drug therapy), Male, Middle Aged, Muscular Diseases (blood), Muscular Diseases (chemically induced), Muscular Diseases (prevention & control), Myalgia (blood), Myalgia (chemically induced), Myalgia (prevention & control), Myositis (blood), Myositis (chemically induced), Myositis (prevention & control), Rhabdomyolysis (blood), Rhabdomyolysis (chemically induced), Rhabdomyolysis (prevention & control), Time Factors.
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal, Anticholesteremic Agents, Atorvastatin Calcium, Ezetimibe, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- chemical , blood : Biomarkers, Cholesterol, LDL, Creatine Kinase.
- chemical , therapeutic use : Antibodies, Monoclonal, Anticholesteremic Agents, Ezetimibe.
- blood : Hypercholesterolemia, Muscular Diseases, Myalgia, Myositis, Rhabdomyolysis.
- chemically induced : Muscular Diseases, Myalgia, Myositis, Rhabdomyolysis.
- drug therapy : Hypercholesterolemia.
- prevention & control : Muscular Diseases, Myalgia, Myositis, Rhabdomyolysis.
- Adult, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
Muscle-related statin intolerance is reported by 5% to 20% of patients.
DOI: 10.1001/jama.2016.3608
PubMed: 27039291
Affiliations:
- Allemagne, Australie, France, Pays-Bas, Royaume-Uni, République tchèque, États-Unis
- Angleterre, Bohême centrale, Californie, Hollande-Septentrionale, Ohio, Oxfordshire, Texas, Écosse, État de New York, Île-de-France
- Amsterdam, Glasgow, Los Angeles, Oxford, Paris, Prague
- Université d'Oxford, Université de Glasgow
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001F89
- to stream PubMed, to step Curation: 001F64
- to stream PubMed, to step Checkpoint: 001F64
- to stream Ncbi, to step Merge: 003356
- to stream Ncbi, to step Curation: 003356
- to stream Ncbi, to step Checkpoint: 003356
- to stream Main, to step Merge: 002012
- to stream Main, to step Curation: 002013
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.</title><author><name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name><affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>University of Amsterdam Faculty of Medicine, Amsterdam, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>University of Amsterdam Faculty of Medicine, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Dent Acosta, Ricardo E" sort="Dent Acosta, Ricardo E" uniqKey="Dent Acosta R" first="Ricardo E" last="Dent-Acosta">Ricardo E. Dent-Acosta</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name><affiliation wicri:level="2"><nlm:affiliation>School of Medicine at Mount Sinai, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Lehman, Sam J" sort="Lehman, Sam J" uniqKey="Lehman S" first="Sam J" last="Lehman">Sam J. Lehman</name><affiliation wicri:level="1"><nlm:affiliation>Flinders University, Bedford Park, SA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Flinders University, Bedford Park, SA</wicri:regionArea><wicri:noRegion>SA</wicri:noRegion></affiliation></author><author><name sortKey="Sattar, Naveed" sort="Sattar, Naveed" uniqKey="Sattar N" first="Naveed" last="Sattar">Naveed Sattar</name><affiliation wicri:level="4"><nlm:affiliation>University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Preiss, David" sort="Preiss, David" uniqKey="Preiss D" first="David" last="Preiss">David Preiss</name><affiliation wicri:level="4"><nlm:affiliation>Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom8Epidemiological Services Unit, University of Oxford, Oxford, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom8Epidemiological Services Unit, University of Oxford, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region><settlement type="city">Oxford</settlement></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital of Paris 6, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Hospital of Paris 6, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Ceska, Richard" sort="Ceska, Richard" uniqKey="Ceska R" first="Richard" last="Ceška">Richard Ceška</name><affiliation wicri:level="3"><nlm:affiliation>Charles University in Prague, Prague, Czech Republic11General University Hospital in Prague, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Charles University in Prague, Prague, Czech Republic11General University Hospital in Prague, Prague</wicri:regionArea><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation></author><author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><affiliation wicri:level="3"><nlm:affiliation>David Geffen School of Medicine at the University of California, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>David Geffen School of Medicine at the University of California</wicri:orgArea></affiliation></author><author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name><affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Baylor College of Medicine, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Gouni Berthold, Ioanna" sort="Gouni Berthold, Ioanna" uniqKey="Gouni Berthold I" first="Ioanna" last="Gouni-Berthold">Ioanna Gouni-Berthold</name><affiliation wicri:level="1"><nlm:affiliation>Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Elliott, Mary" sort="Elliott, Mary" uniqKey="Elliott M" first="Mary" last="Elliott">Mary Elliott</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Brennan, Danielle M" sort="Brennan, Danielle M" uniqKey="Brennan D" first="Danielle M" last="Brennan">Danielle M. Brennan</name><affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Somaratne, Ransi" sort="Somaratne, Ransi" uniqKey="Somaratne R" first="Ransi" last="Somaratne">Ransi Somaratne</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Scott, Rob" sort="Scott, Rob" uniqKey="Scott R" first="Rob" last="Scott">Rob Scott</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Stein, Evan A" sort="Stein, Evan A" uniqKey="Stein E" first="Evan A" last="Stein">Evan A. Stein</name><affiliation wicri:level="2"><nlm:affiliation>Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Metabolic and Atherosclerosis Research Center, Cincinnati</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27039291</idno><idno type="pmid">27039291</idno><idno type="doi">10.1001/jama.2016.3608</idno><idno type="wicri:Area/PubMed/Corpus">001F89</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F89</idno><idno type="wicri:Area/PubMed/Curation">001F64</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F64</idno><idno type="wicri:Area/PubMed/Checkpoint">001F64</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001F64</idno><idno type="wicri:Area/Ncbi/Merge">003356</idno><idno type="wicri:Area/Ncbi/Curation">003356</idno><idno type="wicri:Area/Ncbi/Checkpoint">003356</idno><idno type="wicri:Area/Main/Merge">002012</idno><idno type="wicri:Area/Main/Curation">002013</idno><idno type="wicri:Area/Main/Exploration">002013</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.</title><author><name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name><affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>University of Amsterdam Faculty of Medicine, Amsterdam, the Netherlands.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>University of Amsterdam Faculty of Medicine, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Dent Acosta, Ricardo E" sort="Dent Acosta, Ricardo E" uniqKey="Dent Acosta R" first="Ricardo E" last="Dent-Acosta">Ricardo E. Dent-Acosta</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name><affiliation wicri:level="2"><nlm:affiliation>School of Medicine at Mount Sinai, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Lehman, Sam J" sort="Lehman, Sam J" uniqKey="Lehman S" first="Sam J" last="Lehman">Sam J. Lehman</name><affiliation wicri:level="1"><nlm:affiliation>Flinders University, Bedford Park, SA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Flinders University, Bedford Park, SA</wicri:regionArea><wicri:noRegion>SA</wicri:noRegion></affiliation></author><author><name sortKey="Sattar, Naveed" sort="Sattar, Naveed" uniqKey="Sattar N" first="Naveed" last="Sattar">Naveed Sattar</name><affiliation wicri:level="4"><nlm:affiliation>University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Glasgow, Glasgow</wicri:regionArea><orgName type="university">Université de Glasgow</orgName><placeName><settlement type="city">Glasgow</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Preiss, David" sort="Preiss, David" uniqKey="Preiss D" first="David" last="Preiss">David Preiss</name><affiliation wicri:level="4"><nlm:affiliation>Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom8Epidemiological Services Unit, University of Oxford, Oxford, United Kingdom.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom8Epidemiological Services Unit, University of Oxford, Oxford</wicri:regionArea><placeName><settlement type="city">Oxford</settlement><region type="country">Angleterre</region><region type="comté" nuts="2">Oxfordshire</region><settlement type="city">Oxford</settlement></placeName><orgName type="university">Université d'Oxford</orgName></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation wicri:level="3"><nlm:affiliation>University Hospital of Paris 6, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>University Hospital of Paris 6, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Ceska, Richard" sort="Ceska, Richard" uniqKey="Ceska R" first="Richard" last="Ceška">Richard Ceška</name><affiliation wicri:level="3"><nlm:affiliation>Charles University in Prague, Prague, Czech Republic11General University Hospital in Prague, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Charles University in Prague, Prague, Czech Republic11General University Hospital in Prague, Prague</wicri:regionArea><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation></author><author><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><affiliation wicri:level="3"><nlm:affiliation>David Geffen School of Medicine at the University of California, Los Angeles.</nlm:affiliation><country>États-Unis</country><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName><wicri:orgArea>David Geffen School of Medicine at the University of California</wicri:orgArea></affiliation></author><author><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name><affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine, Houston, Texas.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Baylor College of Medicine, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Gouni Berthold, Ioanna" sort="Gouni Berthold, Ioanna" uniqKey="Gouni Berthold I" first="Ioanna" last="Gouni-Berthold">Ioanna Gouni-Berthold</name><affiliation wicri:level="1"><nlm:affiliation>Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne</wicri:regionArea><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion><wicri:noRegion>Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Elliott, Mary" sort="Elliott, Mary" uniqKey="Elliott M" first="Mary" last="Elliott">Mary Elliott</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Brennan, Danielle M" sort="Brennan, Danielle M" uniqKey="Brennan D" first="Danielle M" last="Brennan">Danielle M. Brennan</name><affiliation wicri:level="2"><nlm:affiliation>Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Somaratne, Ransi" sort="Somaratne, Ransi" uniqKey="Somaratne R" first="Ransi" last="Somaratne">Ransi Somaratne</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Scott, Rob" sort="Scott, Rob" uniqKey="Scott R" first="Rob" last="Scott">Rob Scott</name><affiliation wicri:level="2"><nlm:affiliation>Amgen Inc, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen Inc, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Stein, Evan A" sort="Stein, Evan A" uniqKey="Stein E" first="Evan A" last="Stein">Evan A. Stein</name><affiliation wicri:level="2"><nlm:affiliation>Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Metabolic and Atherosclerosis Research Center, Cincinnati</wicri:cityArea></affiliation></author></analytic><series><title level="j">JAMA</title><idno type="eISSN">1538-3598</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Anticholesteremic Agents (adverse effects)</term><term>Anticholesteremic Agents (therapeutic use)</term><term>Atorvastatin Calcium (adverse effects)</term><term>Biomarkers (blood)</term><term>Cholesterol, LDL (blood)</term><term>Creatine Kinase (blood)</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Ezetimibe (adverse effects)</term><term>Ezetimibe (therapeutic use)</term><term>Female</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)</term><term>Hypercholesterolemia (blood)</term><term>Hypercholesterolemia (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Muscular Diseases (blood)</term><term>Muscular Diseases (chemically induced)</term><term>Muscular Diseases (prevention & control)</term><term>Myalgia (blood)</term><term>Myalgia (chemically induced)</term><term>Myalgia (prevention & control)</term><term>Myositis (blood)</term><term>Myositis (chemically induced)</term><term>Myositis (prevention & control)</term><term>Rhabdomyolysis (blood)</term><term>Rhabdomyolysis (chemically induced)</term><term>Rhabdomyolysis (prevention & control)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticholestérolémiants (effets indésirables)</term><term>Anticholestérolémiants (usage thérapeutique)</term><term>Anticorps monoclonaux (effets indésirables)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Atorvastatine de calcium (effets indésirables)</term><term>Cholestérol LDL (sang)</term><term>Creatine kinase (sang)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hypercholestérolémie (sang)</term><term>Hypercholestérolémie (traitement médicamenteux)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (effets indésirables)</term><term>Maladies musculaires ()</term><term>Maladies musculaires (sang)</term><term>Marqueurs biologiques (sang)</term><term>Myalgie ()</term><term>Myalgie (sang)</term><term>Myosite ()</term><term>Myosite (sang)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Rhabdomyolyse ()</term><term>Rhabdomyolyse (sang)</term><term>Études croisées</term><term>Ézétimibe (effets indésirables)</term><term>Ézétimibe (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Anticholesteremic Agents</term><term>Atorvastatin Calcium</term><term>Ezetimibe</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Cholesterol, LDL</term><term>Creatine Kinase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Anticholesteremic Agents</term><term>Ezetimibe</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hypercholesterolemia</term><term>Muscular Diseases</term><term>Myalgia</term><term>Myositis</term><term>Rhabdomyolysis</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Muscular Diseases</term><term>Myalgia</term><term>Myositis</term><term>Rhabdomyolysis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypercholesterolemia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticholestérolémiants</term><term>Anticorps monoclonaux</term><term>Atorvastatine de calcium</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Ézétimibe</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Muscular Diseases</term><term>Myalgia</term><term>Myositis</term><term>Rhabdomyolysis</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Cholestérol LDL</term><term>Creatine kinase</term><term>Hypercholestérolémie</term><term>Maladies musculaires</term><term>Marqueurs biologiques</term><term>Myalgie</term><term>Myosite</term><term>Rhabdomyolyse</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypercholestérolémie</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticholestérolémiants</term><term>Anticorps monoclonaux</term><term>Ézétimibe</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Maladies musculaires</term><term>Myalgie</term><term>Myosite</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Rhabdomyolyse</term><term>Études croisées</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Muscle-related statin intolerance is reported by 5% to 20% of patients.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>République tchèque</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Bohême centrale</li><li>Californie</li><li>Hollande-Septentrionale</li><li>Ohio</li><li>Oxfordshire</li><li>Texas</li><li>Écosse</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Amsterdam</li><li>Glasgow</li><li>Los Angeles</li><li>Oxford</li><li>Paris</li><li>Prague</li></settlement><orgName><li>Université d'Oxford</li><li>Université de Glasgow</li></orgName></list><tree><country name="États-Unis"><region name="Ohio"><name sortKey="Nissen, Steven E" sort="Nissen, Steven E" uniqKey="Nissen S" first="Steven E" last="Nissen">Steven E. Nissen</name></region><name sortKey="Ballantyne, Christie M" sort="Ballantyne, Christie M" uniqKey="Ballantyne C" first="Christie M" last="Ballantyne">Christie M. Ballantyne</name><name sortKey="Brennan, Danielle M" sort="Brennan, Danielle M" uniqKey="Brennan D" first="Danielle M" last="Brennan">Danielle M. Brennan</name><name sortKey="Dent Acosta, Ricardo E" sort="Dent Acosta, Ricardo E" uniqKey="Dent Acosta R" first="Ricardo E" last="Dent-Acosta">Ricardo E. Dent-Acosta</name><name sortKey="Elliott, Mary" sort="Elliott, Mary" uniqKey="Elliott M" first="Mary" last="Elliott">Mary Elliott</name><name sortKey="Lepor, Norman" sort="Lepor, Norman" uniqKey="Lepor N" first="Norman" last="Lepor">Norman Lepor</name><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name><name sortKey="Scott, Rob" sort="Scott, Rob" uniqKey="Scott R" first="Rob" last="Scott">Rob Scott</name><name sortKey="Somaratne, Ransi" sort="Somaratne, Ransi" uniqKey="Somaratne R" first="Ransi" last="Somaratne">Ransi Somaratne</name><name sortKey="Stein, Evan A" sort="Stein, Evan A" uniqKey="Stein E" first="Evan A" last="Stein">Evan A. Stein</name><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name></region></country><country name="Australie"><noRegion><name sortKey="Lehman, Sam J" sort="Lehman, Sam J" uniqKey="Lehman S" first="Sam J" last="Lehman">Sam J. Lehman</name></noRegion></country><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Sattar, Naveed" sort="Sattar, Naveed" uniqKey="Sattar N" first="Naveed" last="Sattar">Naveed Sattar</name></region><name sortKey="Preiss, David" sort="Preiss, David" uniqKey="Preiss D" first="David" last="Preiss">David Preiss</name></country><country name="France"><region name="Île-de-France"><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name></region></country><country name="République tchèque"><region name="Bohême centrale"><name sortKey="Ceska, Richard" sort="Ceska, Richard" uniqKey="Ceska R" first="Richard" last="Ceška">Richard Ceška</name></region></country><country name="Allemagne"><noRegion><name sortKey="Gouni Berthold, Ioanna" sort="Gouni Berthold, Ioanna" uniqKey="Gouni Berthold I" first="Ioanna" last="Gouni-Berthold">Ioanna Gouni-Berthold</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002013 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002013 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27039291
|texte= Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27039291" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |